Efficacy of a growth hormone-releasing peptide mimetic in cardiac ischemia/reperfusion injury.

Abstract

The cardioprotective efficacy of the pyrazolinone-piperidine dipeptide growth hormone secretagogue (GHS) CP-424,391 was studied in an in vivo rabbit model of ischemia and reperfusion. CP-424,391 was administered at 25 mg/kg p.o. x 7 days. Ischemia was induced by left coronary artery occlusion for 30 min, after which the heart was reperfused for 2 h. At the end of reperfusion, animals were euthanized and the infarct size was determined. The area at risk of infarct was not different between the control (45.8+/-3.7%, n=6) and CP-424,391-treated groups (36.9+/-4.3%, n=11). The infarct size of the control animals was 49.5+/-7.1% and was significantly (P<0.05) lower in the CP-424,391-treated group (infarct size=17.3+/-3.0). There was a trend, albeit not significant, for the left ventricular function to recover to a greater extent in CP-424,391-treated rabbits. Thus, the treatment of rabbits for 7 days with CP-424,391 was cardioprotective against ischemia/reperfusion injury.

• Authors: J T MacAndrew, S S Ellery, M A Parry, L C Pan, S C Black
• Journal: European journal of pharmacology (Eur J Pharmacol) Vol. 432 Issue 2-3 Pg. 195-202 (Dec 07 2001) ISSN: 0014-2999 [Print] Netherlands
• PMID: 11740956 (Publication Type: Journal Article)

Chemical References

• CP 424391
• Piperidines
• Pyrazoles
• Insulin-Like Growth Factor I
• Growth Hormone

Topics

• Animals
• Body Weight (drug effects)
• Dose-Response Relationship, Drug
• Growth Hormone (blood)
• Heart Ventricles (drug effects, pathology)
• Hemodynamics (drug effects)
• Insulin-Like Growth Factor I (metabolism)
• Male
• Myocardial Infarction (etiology, pathology, prevention & control)
• Piperidines (pharmacology)
• Pyrazoles (pharmacology)
• Rabbits
• Reperfusion Injury (complications)
• Time Factors
• Treatment Outcome